Clovis Oncology, Inc. – NASDAQ:CLVS
Founder-led company
Clovis Oncology stock price today
$0.081
-0.03
-32.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Clovis Oncology stock price monthly change
+99.67%
month
Clovis Oncology stock price quarterly change
-87.43%
quarter
Clovis Oncology stock price yearly change
-93.72%
year
Clovis Oncology key metrics
Market Cap | N/A |
Enterprise value | 411.98M |
P/E | -0.03 |
EV/Sales | 4.02 |
EV/EBITDA | -1.97 |
Price/Sales | 0.11 |
Price/Book | -0.02 |
PEG ratio | N/A |
EPS | -1.86 |
Revenue | 103.70M |
EBITDA | -209.12M |
Income | -251.90M |
Revenue Q/Q | -96.45% |
Revenue Y/Y | -33.56% |
Profit margin | -246.1% |
Oper. margin | -225.56% |
Gross margin | 65.2% |
EBIT margin | -225.56% |
EBITDA margin | -201.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeClovis Oncology stock price history
Clovis Oncology stock forecast
Clovis Oncology financial statements
| Dec 2021 | 35.96M | -64.39M | -179.02% |
|---|---|---|---|
| Mar 2022 | 34.24M | -60.16M | -175.69% |
| Jun 2022 | 32.14M | -71.33M | -221.92% |
| Sep 2022 | 1.34M | -56.01M | -4170.81% |
| 2022-05-04 | -0.43 | -0.44 |
|---|---|---|
| 2022-08-08 | -0.41 | -0.5 |
| 2022-11-09 | -0.41 | -0.39 |
| Dec 2021 | 472833000 | 751.67M | 158.97% |
|---|---|---|---|
| Mar 2022 | 451529000 | 754.83M | 167.17% |
| Jun 2022 | 392856000 | 760.55M | 193.6% |
| Sep 2022 | 346775000 | 764.66M | 220.51% |
| Dec 2021 | -41.34M | -69K | 13.16M |
|---|---|---|---|
| Mar 2022 | -58.49M | -62K | 37.85M |
| Jun 2022 | -35.12M | -46K | 9.14M |
| Sep 2022 | -40.61M | -89K | 6.17M |
Clovis Oncology alternative data
| Aug 2023 | 413 |
|---|---|
| Sep 2023 | 413 |
| Oct 2023 | 413 |
| Nov 2023 | 413 |
| Dec 2023 | 413 |
| Jan 2024 | 413 |
| Feb 2024 | 413 |
| Mar 2024 | 413 |
| Apr 2024 | 413 |
| May 2024 | 413 |
| Jun 2024 | 413 |
| Jul 2024 | 413 |
Clovis Oncology other data
43.58%
-10.48%
of CLVS is owned by hedge funds
142
-6
55.98M
-9.54M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2021 | 0 | 18695 |
| Dec 2021 | 0 | 1294 |
| Jan 2022 | 0 | 7 |
| Feb 2022 | 0 | 21946 |
| Mar 2022 | 0 | 50953 |
| Apr 2022 | 0 | 7 |
| May 2022 | 0 | 18901 |
| Jun 2022 | 0 | 11429 |
| Jul 2022 | 0 | 7 |
| Aug 2022 | 0 | 19402 |
| Sep 2022 | 0 | 10937 |
| Oct 2022 | 0 | 6 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HARDING THOMAS C. officer: Senior Vice President .. | Common Stock | 6 | $1.29 | $8 | ||
Option | HARDING THOMAS C. officer: Senior Vice President .. | Restricted Stock Units | 15 | N/A | N/A | ||
Option | HARDING THOMAS C. officer: Senior Vice President .. | Common Stock | 15 | N/A | N/A | ||
Sale | MUEHL DANIEL W officer: Executiv.. | Common Stock | 2,234 | $1.2 | $2,681 | ||
Sale | IVERS-READ GILLIAN C officer: Executiv.. | Common Stock | 2,234 | $1.2 | $2,681 | ||
Sale | GROSS PAUL EDWARD officer: Executiv.. | Common Stock | 2,308 | $1.2 | $2,770 | ||
Sale | HARDING THOMAS C. officer: Executive Vice Preside.. | Common Stock | 172 | $1.2 | $206 | ||
Sale | HARDING THOMAS C. officer: Executive Vice Preside.. | Common Stock | 1,444 | $1.2 | $1,733 | ||
Sale | ROLFE LINDSEY officer: Chief Medical Officer .. | Common Stock | 2,545 | $1.2 | $3,054 | ||
Option | MUEHL DANIEL W officer: Executiv.. | Restricted Stock Units | 5,063 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q2 2022 8 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 4 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 23 Feb 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 3 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Patrick J. Mahaffy (1963) Co-Founder, Chief Executive Officer, Pres & Executive Director | $1,230,000 |
Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM (1968) Executive Vice President of Clinical Devel. & Pharmacovigilance and Chief Medical Officer | $773,080 |
| Dr. Gillian C. Ivers-Read (1954) Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations | $741,940 |
| Mr. Paul Edward Gross (1965) Executive Vice President, Gen. Counsel & Sec. | $726,150 |
| Mr. Daniel W. Muehl (1964) Executive Vice President & Chief Financial Officer | $719,980 |
AstraZeneca: Most Promising Pharmaceutical Company During A Recession
Clovis Oncology: Looking Like An Acquisition Target After Recent Company Updates
Clovis Oncology: Managing A Winning Position After Recent Company Updates
Clovis Oncology: Shares Pop And Drop Around FDA News (Technical Analysis)
ImmunoGen: An Inflection Point In Growth
Myovant: Poised To Overcome Regulatory Issues
Clovis: Shifting Toward Nuclear Medicine
ImmunoGen: Way Beyond SORAYA
Clovis Oncology: Forging A Fresh Perspective
-
What's the price of Clovis Oncology stock today?
One share of Clovis Oncology stock can currently be purchased for approximately $0.08.
-
When is Clovis Oncology's next earnings date?
Unfortunately, Clovis Oncology's (CLVS) next earnings date is currently unknown.
-
Does Clovis Oncology pay dividends?
No, Clovis Oncology does not pay dividends.
-
What is Clovis Oncology's stock symbol?
Clovis Oncology, Inc. is traded on the NASDAQ under the ticker symbol "CLVS".
-
What is Clovis Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Clovis Oncology?
Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the following people:
- Mr. Patrick J. Mahaffy Co-Founder, Chief Executive Officer, Pres & Executive Director(age: 62, pay: $1,230,000)
- Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM Executive Vice President of Clinical Devel. & Pharmacovigilance and Chief Medical Officer(age: 57, pay: $773,080)
- Dr. Gillian C. Ivers-Read Co-Founder, Chief Regulatory Officer & Executive Vice President of Technical Operations(age: 71, pay: $741,940)
- Mr. Paul Edward Gross Executive Vice President, Gen. Counsel & Sec.(age: 60, pay: $726,150)
- Mr. Daniel W. Muehl Executive Vice President & Chief Financial Officer(age: 61, pay: $719,980)
-
Is Clovis Oncology founder-led company?
Yes, Clovis Oncology is a company led by its founders Mr. Patrick J. Mahaffy and Dr. Gillian C. Ivers-Read.
-
How many employees does Clovis Oncology have?
As Jul 2024, Clovis Oncology employs 413 workers.
-
When Clovis Oncology went public?
Clovis Oncology, Inc. is publicly traded company for more then 13 years since IPO on 16 Nov 2011.
-
What is Clovis Oncology's official website?
The official website for Clovis Oncology is clovisoncology.com.
-
Where are Clovis Oncology's headquarters?
Clovis Oncology is headquartered at 5500 Flatiron Pkwy Unit 100, Boulder, COLORADO.
-
How can i contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 Flatiron Pkwy Unit 100, Boulder, COLORADO and company can be reached via phone at +1 303 625 5000.
Clovis Oncology company profile:
Clovis Oncology, Inc.
clovisoncology.comExchange:
NASDAQ
Full time employees:
413
Industry:
Biotechnology
Sector:
Healthcare
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
5500 Flatiron Pkwy Unit 100
Boulder, COLORADO 80301
Boulder, COLORADO 80301
CIK: 0001466301
ISIN: US1894641000
CUSIP: 189464100
